Pantoprazol Aristo (Pantoprazole Sodium Sesquihydrate)

Pantoprazol Aristo is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related conditions:

• Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the oesophageal lining.
• Erosive oesophagitis: accelerates mucosal healing and reduces further erosion.
• Peptic ulcer disease: supports ulcer healing and helps prevent recurrence.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with the condition.

• Pantoprazole selectively inhibits the H+/K+‑ATPase enzyme (the gastric proton pump) on the secretory surface of parietal cells. By binding irreversibly to this pump, it blocks the final step of acid production, leading to a sustained reduction in gastric acidity and allowing damaged mucosa to heal.

Pantoprazol Aristo may cause a range of adverse reactions. Most are mild and transient, but some require medical attention.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhoea: watery stools without blood.
• Nausea: occasional feeling of queasiness.
• Abdominal pain: mild cramping or discomfort.
• Flatulence: increased intestinal gas.
• Constipation: infrequent, hard stools.

Serious or Rare Side Effects

• Severe allergic reaction: rash, itching, swelling, or difficulty breathing.
• Clostridioides difficile infection: persistent diarrhoea with abdominal pain.
• Low magnesium levels: muscle cramps, irregular heartbeat, or seizures.
• Bone fractures: increased risk with long‑term use.
• Liver enzyme elevation: signs of hepatitis such as jaundice.
• Acute interstitial nephritis: kidney inflammation presenting with reduced urine output.

When prescribing Pantoprazol Aristo, clinicians should consider several safety aspects:

• Assess renal function: dose adjustment may be needed in severe impairment.
• Review concomitant medications: potential for reduced efficacy of drugs requiring acidic pH.
• Monitor long‑term use: evaluate need for continued therapy after 8‑12 weeks.
• Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment.
• Elderly patients: start with the lowest effective dose and monitor for fractures.
• Store at ambient temperature: keep below 25°C, protect from moisture and light in the original packaging.

Pantoprazol Aristo can affect the absorption or metabolism of several medicines. Interaction risk varies from major to moderate.

Major Interactions (Avoid)

• Atazanavir: reduced antiviral absorption leading to therapeutic failure.
• Nelfinavir: decreased plasma concentrations compromising HIV treatment.
• Dasatinib: lowered exposure may reduce anticancer efficacy.

Moderate Interactions (Monitor Closely)

• Warfarin: possible increase in INR; monitor coagulation parameters.
• Methotrexate: reduced renal clearance may raise toxicity risk.
• Digoxin: modest rise in serum levels; observe for signs of toxicity.